For the quarter ending 2025-09-30, CTMX had -$14,856K decrease in cash & cash equivalents over the period. -$15,421K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | -14,229 | 23,371 |
| Amortization of intangible assets | 36 | 73 |
| Depreciation and amortization | 98 | 659 |
| Accretion of discounts on short-term investments | 636 | 851 |
| Stock-based compensation expense | 1,384 | 3,439 |
| Non-cash lease expense | -1,133 | -2,189 |
| Accounts receivable | -240 | -1,234 |
| Prepaid expenses and other assets | -708 | 1,076 |
| Accounts payable | 419 | -853 |
| Accrued liabilities and other long-term liabilities | -326 | -3,209 |
| Deferred revenue | -4,375 | -61,772 |
| Net cash used in operating activities | -15,548 | -36,796 |
| Purchases of property and equipment | -127 | 146 |
| Purchases of short term investments | 19,688 | 128,618 |
| Maturities of short-term investments | 20,000 | 83,000 |
| Net cash (used in) provided by investing activities | 439 | -45,764 |
| Proceeds from issuance of common stock, net of issuance costs | 0 | 93,373 |
| Proceeds from employee purchase plan and exercise of stock options | 253 | 177 |
| Net cash provided by financing activities | 253 | 93,550 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -14,856 | 10,990 |
| Cash and cash equivalents at beginning of period | 39,079 | - |
| Cash and cash equivalents at end of period | 35,213 | - |
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX)